Similarly, SCN− supplementation in atherosclerosis-prone Ldlr−/− mice transgenic for human MPO decreased the total plaque area with no changes to serum MPO concentrations between SCN− supplemented and control mice [44]. The gene discussed is MPO; the disease is atherosclerosis.